Join the Lupus Erythematosus group to help and get support from people like you.
Lupus Erythematosus News
Related terms: Discoid Lupus Erythematosus, DLE
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 – Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study published online July 10...
Scientists Spot Cause of Lupus, Way to Reverse It
THURSDAY, July 11, 2024 – Lupus is caused by a specific defect in the immune system that can be reversed, potentially curing the autoimmune disorder, a new study claims. The disease appears to be...
Air Pollutant Exposure Linked to Increased Risk for Incident Lupus
WEDNESDAY, July 10, 2024 – Air pollutant exposure is associated with an increased likelihood of developing incident systemic lupus erythematosus (SLE), according to a study published online July 10...
FDA Approves Belimumab Autoinjector for Pediatric Systemic Lupus Erythematosus
WEDNESDAY, May 22, 2024 – The U.S. Food and Drug Administration has approved a 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active...
FDA Approves Benlysta (belimumab) Autoinjector for Children with Systemic Lupus Erythematosus
Philadelphia, PA May 20 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg subcutaneous route of administration of Benlysta...
CAR T-Cell Therapy Feasible, Safe for Autoimmune Diseases
WEDNESDAY, Feb. 21, 2024 – CD19 chimeric antigen receptor (CAR) T-cell therapy seems feasible, safe, and efficacious for patients with different autoimmune diseases, according to a study published...
GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above
London UK, Philadelphia USA April 26, 2019 – GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of...
GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (belimumab) for Systemic Lupus Erythematosus
London, UK 21 July 2017 – GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients...
FDA Approves Benlysta to Treat Lupus
March 9, 2011 – The U.S. Food and Drug Administration today approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving...
Further information
Related condition support groups
Systemic Lupus Erythematosus, Autoimmune Disorders